The proposed General Assembly Raised Bill No. 1355 aims to strengthen the regulation of nonsterile compounding pharmacies and pharmaceutical marketing firms in Connecticut. It requires the Commissioner of Consumer Protection, in collaboration with the Commission of Pharmacy, to establish regulations that ensure compliance with state laws and United States Pharmacopeia standards for nonsterile compounding pharmacies. The bill highlights the importance of accessibility to compounded pharmaceutical products containing active ingredients such as levonorgestrel, mifepristone, or misoprostol, and allows the Department of Consumer Protection to import these drugs to enhance patient access. Additionally, it introduces provisions that permit licensed veterinarians to authorize individuals to dispense prescription veterinary drugs under their supervision.

The legislation also repeals existing provisions related to pharmaceutical marketing firms, replacing them with new requirements for annual registration and detailed reporting of representatives' activities. Notably, the previous mandate for the department to post the latest list of pharmaceutical representatives on its website has been removed. Instead, the bill stipulates that pharmaceutical marketing firms must inform the department of any changes in their representatives' employment status and submit annual performance reports on their interactions with healthcare practitioners. These changes aim to improve transparency and accountability in pharmaceutical marketing while ensuring safe dispensing practices for veterinary drugs.

Statutes affected:
Raised Bill: